Filing Analysis
Q/C Technologies, Inc. has terminated its Technology License and Development Agreement with LightSolver Ltd., effectively exiting the cryptocurrency mining hardware space. The company is pivoting its entire operational focus toward a proprietary silicon photonic computing architecture for AI inference.
🚩 Red Flags
- Complete abandonment of previous core business model (cryptocurrency mining hardware) in favor of unproven technology (optical computing).
- High execution risk associated with the pivot to silicon photonics for AI.
- Significant capital expenditure implied by the establishment of a new 4,800-sq-ft laboratory and relocation.
📋 Key Facts
- Terminated Technology License and Development Agreement with LightSolver Ltd. effective June 26, 2026.
- The termination relieves LPU Holdings LLC (a subsidiary) from further milestone payments to LightSolver.
- Company is pivoting focus entirely to its 'Optical Processing Unit' (OPU) initiative for AI inference.
- Relocating headquarters to San Francisco, CA, and establishing a 4,800-square-foot integrated photonics laboratory.
- Strategic Advisors include Martin Shkreli and James Altucher.
Q/C Technologies, Inc. dismissed its independent auditor, Stephano Slack LLC, and appointed Grassi & Co., CPAs, P.C. on March 9, 2026. The previous auditor's reports for fiscal years 2023 and 2024 included a going concern qualification due to net losses and negative cash flows.
🚩 Red Flags
- Going concern qualification: The former auditor's report for 2023 and 2024 noted substantial doubt about the company's ability to continue as a going concern.
- Auditor change while under financial distress: Changing auditors while a going concern doubt exists can be a risk indicator for micro-cap companies.
📋 Key Facts
- Dismissal of Stephano Slack LLC effective March 9, 2026.
- Appointment of Grassi & Co., CPAs, P.C. effective March 9, 2026.
- Stephano Slack's reports for the fiscal years ended December 31, 2024, and 2023, contained a going concern paragraph.
- The company reported no disagreements or reportable events with the former auditor from October 3, 2023, through the dismissal date.
- The company is listed on the Nasdaq Capital Market under the ticker QCLS.
Q/C Technologies, Inc. entered into a consulting agreement with Chelsea Voss and appointed her to the Board of Directors. The appointment is notable due to Ms. Voss's background at OpenAI and the fact that she was introduced by an affiliate of Martin Shkreli.
🚩 Red Flags
- Related-party connection: The new director was introduced via an affiliate of Martin Shkreli, who is a consultant to the company.
- Potential dilution: Significant issuance of RSUs and stock options (425,000 total equity instruments) to a single individual.
📋 Key Facts
- Chelsea Voss appointed to the Board of Directors on January 16, 2026.
- Consulting agreement term is 12 months unless terminated earlier.
- Monthly consulting fee: $12,500 ($150,000 annually) payable in arrears.
- Compensation includes 212,500 RSUs vesting in four quarterly installments.
- Compensation includes options to purchase up to 212,500 shares of common stock at an exercise price of the greater of $5.097 or FMV.
- Ms. Voss was introduced to the Company by Martin Shkreli (an affiliate of Ocean Avenue Holdings LLC), a consultant for the Company.
Q/C Technologies, Inc. entered into a 12-month consulting agreement with Ocean Avenue Holdings LLC, an entity affiliated with Martin Shkreli. The agreement involves monthly cash fees and the issuance of warrants and restricted stock to the consultant.
🚩 Red Flags
- Related-party transaction involving an entity affiliated with Martin Shkreli, a highly controversial figure in the financial markets.
- Issuance of equity (warrants and restricted stock) to a consultant as part of compensation structure.
- Potential for significant dilution via the 212,500 warrants and 212,500 restricted shares.
📋 Key Facts
- Consulting Agreement signed on December 8, 2025, with Ocean Avenue Holdings LLC (affiliated with Martin Shkreli).
- Monthly fee of $12,500 ($150,000 annually) payable in arrears.
- Issuance of warrants to purchase up to 212,500 shares of common stock at an exercise price of $5.097 per share.
- Grant of 212,500 restricted shares of Common Stock subject to quarterly vesting over one year.
- Warrants and shares are subject to ownership limitations (4.99% or 9.99%).
- The transaction was conducted via Section 4(a)(2) exemption from registration.
Q/C Technologies, Inc. held a special meeting where stockholders approved several significant measures, including an amendment to the 2021 Equity Incentive Plan and authorization for a potential reverse stock split ranging from 1-for-2 to 1-for-250.
🚩 Red Flags
- Approval of a wide-ranging reverse stock split (up to 1-for-250) is a major red flag often used to maintain Nasdaq listing compliance due to low share prices.
- Significant potential dilution: The approved issuance proposal includes shares/warrants that could equal or exceed 20% of common stock outstanding.
- Complex capital structure with multiple series of preferred stock (Series D, G, H, and I) and various warrants issued to placement agents, consultants, and investors.
📋 Key Facts
- Stockholders approved increasing the total shares available under the 2021 Equity Incentive Plan by 1,375,000 shares, bringing the total to 1,400,000 shares.
- Stockholders approved a proposal allowing the Board discretion to implement a reverse stock split with a ratio between 1-for-2 and 1-for-250 prior to the one-year anniversary of the split's approval.
- Stockholders approved an issuance proposal (Nasdaq Rule 5635(d) compliance) involving various warrants, Series H/I preferred stock, and advisory shares totaling up to 20% of common stock outstanding.
- The meeting was reconvened on November 14, 2025, after being adjourned from November 10, 2025.
Q/C Technologies, Inc. filed an amendment to its previous 8-K to include omitted information regarding the grant of Restricted Stock Units (RSUs) to several directors and officers. The grants consist of both immediately vested units and units contingent upon stockholder approval for increasing the equity incentive plan capacity.
🚩 Red Flags
- Related-party transactions: Significant equity compensation granted directly to directors and executive officers.
- Omission error: The company failed to report these material compensatory arrangements in the original 8-K filed on October 3, requiring an amendment (8-K/A).
- Dilution risk: A significant portion of the RSUs is contingent upon stockholder approval for increasing the share reserve.
📋 Key Facts
- Amendment filed on October 6, 2025, to correct an omission in the October 3, 2025, filing.
- Total of 225,000 RSUs granted across several directors and officers.
- Initial Grants (8,644 + 2,161 + 2,161 + 2,161 + 1,080 + 1,080 = 17,247 RSUs) were issued and fully vested on October 3, 2025.
- Additional Grants (91,356 to Silverman; 22,839 each to Schriber, White, Friscia; 11,420 each to Glass, Rauch; 25,000 to Bernstein) vest upon stockholder approval of an increase in the 2021 Equity Incentive Plan.
- Recipients include Executive Chairman Joshua Silverman and other board members/officers.
Q/C Technologies, Inc. entered into an Omnibus Waiver and Amendment with existing preferred stockholders to modify registration rights and 'Excluded Securities' definitions. Additionally, the company entered a two-year consulting agreement with James Altucher and Z-List Media involving the issuance of up to 400,000 warrants.
🚩 Red Flags
- Waiver of failure to file Registration Statement by the required deadline suggests potential compliance issues or delays in SEC filings.
- Issuance of 400,000 warrants to consultants (James Altucher/Z-List Media) represents significant potential dilution for existing shareholders.
- The use of 'Omnibus Waivers' and amendments to 'Excluded Securities' often indicates a need to manage complex capital structures or prevent technical defaults by the company.
📋 Key Facts
- Entered into an Omnibus Waiver and Amendment on September 30, 2025, regarding Series H convertible preferred stock.
- The Amendment includes a waiver for failure to file a Registration Statement by the original Filing Deadline.
- Modified 'Excluded Securities' definition to include common stock issued under an Approved Stock Plan up to 15.0% of outstanding shares/convertibles.
- Entered into a consulting agreement with James Altucher and Z-List Media, Inc. on October 1, 2025.
- Issued warrants to Z-List Media, Inc. for up to 400,000 shares of common stock across four tranches at exercise prices ranging from $5.00 to $10.00.
- Board approved RSU grants to five directors/officers totaling 200,000 units, with a significant portion contingent on stockholder approval for plan increases.
Q/C Technologies, Inc. (formerly TNF Pharmaceuticals, Inc.) has completed a corporate rebranding involving a name change and a ticker symbol change to 'QCLS' on the Nasdaq.
🚩 Red Flags
- Rebranding can sometimes be used by micro-cap companies to signal a pivot in business model, though no specific strategic shift is detailed in this filing.
📋 Key Facts
- Company changed name from 'TNF Pharmaceuticals, Inc.' to 'Q/C Technologies, Inc.' effective September 22, 2025.
- Ticker symbol changed from 'TNFA' to 'QCLS' effective before market open on September 25, 2025.
- The name change was executed via a Certificate of Amendment to the Certificate of Incorporation under Delaware law.
- No change to CUSIP number or security holder rights occurred as part of this rebranding.
TNF Pharmaceuticals closed a complex series of transactions involving the issuance of Series H Preferred Stock and an acquisition of LPU Holdings LLC via equity. The filing also details significant restructuring of existing Series F debt, including maturity extensions and removal of amortization requirements.
🚩 Red Flags
- Significant Dilution Risk: The Series H Preferred Stock and warrants represent potential issuance of up to 2.8 million common shares, which is highly dilutive.
- Complex Capital Structure: Multiple layers of preferred stock (Series F, F-1, I, and H) indicate a highly leveraged/complex equity structure typical of distressed micro-caps.
- Debt Restructuring: The extension of maturity dates for Series F debt suggests the company was unable to meet original repayment schedules or amortization terms.
📋 Key Facts
- Closed 'Series H' Private Placement: 7,000 shares of Series H Convertible Preferred Stock issued to accredited investors.
- Series H Conversion Terms: Initially convertible into up to 1,400,000 shares of Common Stock at $5.00/share; includes warrants for 1,400,000 shares at $5.00 exercise price.
- Asset Acquisition: Acquired 100% of LPU Holdings LLC via the issuance of Series I Convertible Preferred Stock (convertible into 747,362 common shares).
- Debt Restructuring: Amended Series F and Series F-1 Preferred Stock to extend maturity dates to March 2, 2027.
- Amortization Relief: Removed amortization payments and related covenants from the Series F and Series F-1 debt terms.
TNF Pharmaceuticals, Inc. filed an 8-K/A to supplement its previous filing regarding the acquisition of 100% of the membership interests in LPU Holdings LLC. The transaction involves the issuance of Series I Convertible Preferred Stock convertible into 747,362 shares of common stock.
🚩 Red Flags
- Issuance of convertible preferred stock can lead to significant dilution for existing common shareholders upon conversion.
📋 Key Facts
- Acquisition of 100% membership interests of LPU Holdings LLC from its members.
- Consideration consists of Series I Convertible Preferred Stock convertible into 747,362 shares of Common Stock.
- The deal includes a Support Agreement and a Registration Rights Agreement with the Sellers.
- A License Agreement was executed between LPU Holdings LLC, LightSolver Ltd. (an Israeli company), and TNF Pharmaceuticals.
TNF Pharmaceuticals, Inc. entered into a $7 million private placement of Series H convertible preferred stock and warrants to accredited investors. The deal includes significant dilution potential via a 200% registration coverage requirement and features a 'full ratchet' anti-dilution provision on warrants.
🚩 Red Flags
- Significant dilution: The conversion feature allows for up to 1,400,000 new shares from only 7,000 preferred shares.
- Full Ratchet Anti-Dilution: Warrants are subject to full ratchet adjustments, which is highly dilutive to existing shareholders in down rounds.
- High Dividend/Penalty Rate: Dividends jump from 7% to 15% upon triggering events (e.g., failure to maintain registration effectiveness).
- Registration Risk: The company faces liquidated damages if it fails to make the registration statement effective promptly.
- Liquidity Pressure: The Omnibus Amendment extended maturity dates for Series F/F-1 preferred stock to March 2, 2027, suggesting a need to push back debt obligations.
📋 Key Facts
- Total gross proceeds from the Private Placement: $7,000,000.
- Issuance of 7,000 shares of Series H convertible preferred stock at $1,000 per share.
- Preferred Stock converts into up to 1,400,000 shares of common stock at an initial price of $5.00.
- Warrants issued for up to 1,400,000 shares of common stock with a $5.00 exercise price.
- Preferred Stock carries a 7% cash dividend, increasing to 15% upon a 'Triggering Event'.
- The company must file a registration statement for 200% of the Conversion and Warrant shares within 15 days of closing.
- Warrants include a 'full ratchet' anti-dilution adjustment if common stock is issued below $5.00.
TNF Pharmaceuticals, Inc. held its 2025 annual meeting where stockholders approved several significant structural changes, including a massive increase in authorized common shares and authorization for a potential reverse stock split.
🚩 Red Flags
- Approval of a reverse stock split (ratio up to 1-for-100) is a major red flag often used to maintain Nasdaq listing compliance or manipulate share price.
- Massive increase in authorized shares (from 250M to 1.25B) suggests significant potential dilution for existing shareholders via future offerings.
📋 Key Facts
- Stockholders approved an amendment to increase authorized common stock from 250 million to 1.25 billion shares.
- Stockholders approved a proposal authorizing the Board to implement a reverse stock split with a ratio between 1-for-2 and 1-for-100 at their discretion.
- The Board was authorized to increase the stated value of Series F and Series F-1 Convertible Preferred Stock up to $1,125 per share (previously $1,000).
- Six directors were elected to serve until the 2026 annual meeting: Mitchell Glass, Christopher C. Schreiber, Joshua Silverman, Jude Uzonwanne, Bill J. White, and Stephen Friscia.
- Stephano Slack LLC was ratified as the independent auditor for fiscal year 2025.
TNF Pharmaceuticals, Inc. has amended its bylaws to change the voting threshold required for stockholder approval on matters other than the election of directors.
🚩 Red Flags
- Lowering the voting threshold can make it easier for management or large shareholders to pass resolutions with less total shareholder participation/consensus.
📋 Key Facts
- The Board approved the 'First Amendment' to the Bylaws effective May 9, 2025.
- Amends Article II, Section 2.09 regarding voting requirements.
- Changes the threshold for non-director matters from a majority of shares present/represented (which includes abstentions) to a majority of votes cast (excluding abstentions and broker non-votes).
- Directors will continue to be elected by plurality vote.
TNF Pharmaceuticals, Inc. announced the date and format for its 2025 Annual Meeting of Stockholders, scheduled for May 20, 2025.
📋 Key Facts
- The 2025 Annual Meeting will be held virtually via remote communication on May 20, 2025, at 10:00 a.m. ET.
- Due to the meeting date being shifted more than 30 days from the anniversary of the 2024 meeting, specific deadlines for stockholder proposals and director nominations have been set.
- The deadline for submission of qualified stockholder proposals (Rule 14a-8) or director nominations is April 18, 2025.
TNF Pharmaceuticals received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days between January 30, 2025, and March 14, 2025. The company has been granted a 180-day compliance period ending September 15, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price requirement ($1.00)
- Potential for an imminent reverse stock split to avoid delisting
- Risk of being unable to qualify for a second 180-day compliance period
📋 Key Facts
- Received Nasdaq deficiency letter on March 17, 2025.
- Violation of Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price of $1.00.
- Compliance period granted until September 15, 2025 (180 days).
- To regain compliance, the stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.
- The company may need to effect a reverse stock split to satisfy requirements if it cannot regain compliance through market performance.
TNF Pharmaceuticals, Inc. held a telephonic conference call on March 6, 2025, to discuss research and development progress regarding its lead compound, Isomyosamine.
📋 Key Facts
- Conference call date: March 6, 2025
- Subject matter: R&D progress of lead compound 'Isomyosamine'
- The information was disclosed under Item 7.01 (Regulation FD Disclosure)
- A transcript of the call is provided as Exhibit 99.1
TNF Pharmaceuticals held its 2024 annual meeting of stockholders on November 25, 2024. Shareholders approved the election of seven directors, an amendment to increase the shares available under the 2021 Equity Incentive Plan, and the ratification of Stephano Slack LLC as the independent auditor.
🚩 Red Flags
- Significant increase in equity incentive plan (over 2.2 million new shares) may lead to future dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on November 25, 2024.
- Stockholders approved increasing the TNF Pharmaceuticals, Inc. 2021 Equity Incentive Plan by 2,259,060 shares, bringing the total to 2,500,000 shares.
- Seven directors were elected: Mitchell Glass, Craig Eagle, Christopher C. Schreiber, Joshua Silverman, Jude Uzonwanne, Bill J. White, and Stephen Friscia.
- Stephano Slack LLC was ratified as the independent registered public accounting firm for fiscal year 2024.
- The meeting included a proposal to adjourn the meeting if necessary to solicit further proxies, which was approved.
TNF Pharmaceuticals, Inc. entered into a Stock Purchase Agreement with Prevail Partners, LLC to sell 283,019 shares of common stock at $2.12 per share. The transaction is a private placement intended to raise $600,000 for general corporate purposes and working capital.
🚩 Red Flags
- Small transaction size ($600k) suggests limited liquidity runway
- Potential related-party flow: The company may use proceeds to satisfy invoices to an affiliate of the purchaser (InfoWorks).
📋 Key Facts
- Date of Agreement: October 1, 2024
- Total Shares Sold: 283,019 shares of common stock
- Price per Share: $2.12 (representing 120% of the 30-day VWAP)
- Gross Proceeds: $600,000
- Investor: Prevail Partners, LLC (an accredited investor)
- Use of Proceeds: General corporate purposes and working capital; option to pay affiliate InfoWorks directly for existing service invoices.
TNF Pharmaceuticals announced the resignation of its independent auditor, Morison Cogen LLP, effective September 30, 2024, as the firm exits the public company audit market. The company has appointed Stephano Slack LLC as its new auditor for the fiscal year ending December 31, 2024.
🚩 Red Flags
- Going concern language: The previous auditor noted substantial doubt about the company's ability to continue as a going concern due to net losses and negative cash flows.
- Auditor change: While the reason cited is the firm's exit from public audits, auditor changes in micro-caps often require heightened scrutiny regarding financial stability.
📋 Key Facts
- Morison Cogen LLP resigned on September 30, 2024, due to their exit from providing audit services to publicly traded companies.
- Stephano Slack LLC was engaged as the new independent auditor on October 3, 2024.
- The previous auditor's reports for fiscal years ended Dec 31, 2023, and Dec 31, 2022, included a 'going concern' qualification due to net losses and negative cash flows.
- No disagreements regarding accounting principles or auditing procedures were reported between the company and the outgoing auditor.
TNF Pharmaceuticals, Inc. announced the scheduling of its 2024 Annual Meeting of Stockholders for November 25, 2024. The filing includes important deadlines for stockholder proposals and director nominations in compliance with SEC rules.
📋 Key Facts
- 2024 Annual Meeting scheduled for Monday, November 25, 2024.
- Record date for stockholders entitled to vote is October 18, 2024.
- Deadline for Rule 14a-8 stockholder proposals and director nominations is October 3, 2024.
- The meeting date was changed by more than 30 days from the anniversary of the previous year's meeting.
TNF Pharmaceuticals, Inc. entered into an Amendment Agreement with holders of Series G Convertible Preferred Stock to amend the method by which 'in kind' dividend shares are determined. This follows a previously disclosed May 20, 2024 Securities Purchase Agreement involving convertible preferred stock and warrants.
🚩 Red Flags
- Continued modification of terms for convertible preferred stock suggests ongoing negotiations with debt/equity holders.
- The use of 'in kind' dividend mechanisms in convertible instruments can lead to significant dilution for common shareholders.
📋 Key Facts
- On August 8, 2024, the Company entered into an Amendment Agreement with Required Holders of Series G Convertible Preferred Stock.
- The amendment modifies how the number of shares issued for 'in kind' dividends is determined via a Certificate of Amendment filed with the Secretary of State.
- This relates to a prior Securities Purchase Agreement (SPA) dated May 20, 2024, which included Series G Convertible Preferred Stock and warrants.
TNF Pharmaceuticals held a special meeting of stockholders on July 24, 2024, where shareholders approved a massive increase in authorized common stock from approximately 16.7 million to 250 million shares. The meeting also included votes on the issuance of shares underlying convertible preferred stock and warrants to comply with Nasdaq rules.
🚩 Red Flags
- Massive increase in authorized share count (over 14x current level) indicates significant potential for future dilution.
- The need to seek shareholder approval for issuances exceeding 20% of outstanding stock suggests the company is navigating Nasdaq compliance requirements related to large equity issuances/convertibles.
📋 Key Facts
- Shareholders approved an amendment to increase authorized common stock from 16,666,666 to 250,000,000 shares.
- The 'Issuance Proposal' was approved to allow the issuance of shares underlying Series F-1 Preferred Stock, Series G Preferred Stock, and warrants in an amount exceeding 20% of outstanding common stock (to comply with Nasdaq Rule 5635(d).
- Morison Cogen LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
- The Share Increase Proposal passed with 819,760 votes in favor and 73,259 against.
TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.) has officially changed its corporate name and ticker symbol. The company transitioned from 'MYMD' to 'TNFA' on the Nasdaq Stock Market effective July 24, 2024.
📋 Key Facts
- Company name changed from 'MyMD Pharmaceuticals, Inc.' to 'TNF Pharmaceuticals, Inc.' effective July 22, 2024.
- Ticker symbol changed from 'MYMD' to 'TNFA' on the Nasdaq Stock Market, effective before market open on July 24, 2024.
- The name change was executed via a Certificate of Amendment to the Certificate of Incorporation under Delaware General Corporation Law.
- No changes were made to the CUSIP or the rights of security holders.
MyMD Pharmaceuticals amended its Certificate of Designations to drastically increase the authorized number of Series G Convertible Preferred Stock shares. This follows a previously disclosed securities purchase agreement with accredited investors.
🚩 Red Flags
- Massive increase in authorized preferred stock (from ~9k to over 12.8 million) suggests significant potential dilution for existing common shareholders.
- The ability to pay dividends 'in kind' via additional preferred shares is a mechanism often used by companies with limited cash flow to satisfy obligations without depleting cash reserves.
📋 Key Facts
- The Company filed a Certificate of Amendment on June 17, 2024.
- Authorized shares of Preferred Stock increased from 8,950 to 12,826,273.
- The increase is intended to allow for the payment of dividends 'in kind' via additional shares of Preferred Stock.
- This action stems from a Securities Purchase Agreement entered into on May 20, 2024.
MyMD Pharmaceuticals entered into two significant private placement agreements (Series G and Series F-1) to raise approximately $13.9 million in gross proceeds via convertible preferred stock and warrants. The filing includes an amendment to correct typographical errors from a previous report.
🚩 Red Flags
- Highly Dilutive Terms: The conversion of preferred stock into common stock represents a massive potential dilution (up to ~4.9M shares for Series G alone).
- Death Spiral/Variable Conversion Features: The Series F-1 redemption allows settlement in shares at the lower of the conversion price or 80% of the average trading price, creating significant downward pressure on the stock.
- Mandatory Redemption: The company is obligated to redeem Series F-1 in cash or shares starting Dec 2024, which may strain liquidity.
- Triggering Events: Failure to make payments can trigger a mandatory cash redemption at a premium.
📋 Key Facts
- Series G Private Placement: Expected gross proceeds of $8.9 million for 8,950 shares of Series G Convertible Preferred Stock.
- Series F-1 Private Placement: Expected gross proceeds of $5.0 million for 5,050 shares of Series F-1 Convertible Preferred Stock.
- Conversion Price: Both series have an initial conversion price of $1.816 per share.
- Redemption Terms: Series F-1 Preferred Stock must be redeemed in seven equal monthly installments starting December 1, 2024.
- Dividend Rate: Series F-1 carries a 10% annual dividend (compounded monthly), which increases to 15% upon a 'Triggering Event'.
- Stockholder Approval Required: The company must seek stockholder approval by August 1, 2024, for issuances exceeding 19.99% of outstanding shares and for increasing authorized share count.
- Placement Agents: GP Nurmenkari Inc. and Palladium Capital Group, LLC are acting as non-exclusive placement agents.
MyMD Pharmaceuticals underwent a significant management overhaul following a recent securities offering. This includes the departure of the President and CMO, Christopher Chapman, M.D., and the appointment of Mitchell Glass, M.D., as the new President and CMO.
🚩 Red Flags
- Management turnover triggered by a financing event (SPA) often indicates investor-mandated changes in leadership.
- Massive increase in authorized Preferred Stock (from ~9k to over 12M shares) suggests significant potential dilution or the need for large 'in kind' dividend distributions to lenders/investors.
- The appointment of a board member via a specific investor nomination right (PharmaCyte Biotech, Inc.) indicates loss of control to creditors/investors.
📋 Key Facts
- Dr. Christopher Chapman resigned as President, CMO, and Board member effective June 14, 2024.
- The separation was described as 'amicable' and part of an agreed management change associated with a recent Securities Purchase Agreement (SPA).
- Dr. Chapman will receive $125,000 in monthly installments, a $25,000 one-time payment, and 3 months of COBRA coverage.
- Mitchell Glass, M.D., appointed as President and CMO effective June 13, 2024; he is an existing Board member with extensive life sciences experience.
- Stephen Friscia was appointed to the Board via a nomination right granted to PharmaCyte Biotech, Inc. pursuant to the May 20, 2024 SPA.
- The company amended its Certificate of Designations to increase authorized Series G Preferred Stock from 8,950 to 12,826,273 shares to allow for 'in kind' dividend payments.
MyMD Pharmaceuticals completed two private placements (Series F-1 and Series G) totaling $14 million in gross proceeds. The offering involved the issuance of convertible preferred stock and warrants, which will result in significant potential dilution for existing shareholders.
🚩 Red Flags
- Significant potential dilution: The total number of common shares issuable via conversion and warrants exceeds 13 million shares, which is substantial for a micro-cap.
- Convertible Preferred Stock: Often used by distressed or cash-strapped companies to attract capital, typically carrying terms favorable to the investor over common shareholders.
📋 Key Facts
- Completed Private Placements for aggregate gross proceeds of $14 million (before fees/expenses).
- Series G placement: 8,950 shares of Series G Convertible Preferred Stock; convertible into up to 4,928,415 common shares.
- Series F-1 placement: 5,050 shares of Series F-1 Convertible Preferred Stock; convertible into up to 2,780,837 common shares.
- Conversion price for both series is set at $1.816 per share.
- Warrants were issued alongside preferred stock in both placements with an exercise price of $1.816 per share.
MyMD Pharmaceuticals entered into two significant private placement agreements (Series G and Series F-1) to raise approximately $13.9 million in aggregate gross proceeds through the sale of convertible preferred stock and warrants. The transactions involve highly dilutive terms, including conversion prices subject to downward adjustments and mandatory stockholder approval for issuances exceeding 19.99% of outstanding shares.
🚩 Red Flags
- Highly dilutive financing structure involving large numbers of convertible preferred shares and warrants.
- Downward price-based adjustment clauses in the conversion price (anti-dilution protection for investors).
- Mandatory redemption requirements for Series F-1 Preferred Stock creating potential cash flow pressure.
- Requirement for stockholder approval due to Nasdaq Rule 5635(d) compliance regarding large issuances.
📋 Key Facts
- Series G Private Placement: Expected $8.9 million in gross proceeds via Series G Convertible Preferred Stock.
- Series F-1 Private Placement: Expected $5.0 million in gross proceeds via Series F-1 Convertible Preferred Stock.
- Conversion Price: Both series have an initial conversion price of $1.816 per share, subject to downward adjustments if shares are issued below this price.
- Warrants: Issuance of significant short-term and long-term warrants for both series at an exercise price of $1.816 per share.
- Dividends: Series G Preferred Stock carries a 10% annual dividend, compounding monthly, which increases to 15% upon a 'Triggering Event'.
- Stockholder Approval: The company must seek stockholder approval by August 1, 2024, for issuances exceeding 19.99% of outstanding shares under Nasdaq Rule 5635(d).
- Redemption Terms: Series F-1 Preferred Stock requires redemption in eight equal monthly installments starting shortly after closing.
MyMD Pharmaceuticals announced the immediate resignation of its Chief Scientific Officer, Adam Kaplin, M.D., Ph.D., effective April 15, 2024. The company explicitly stated that the resignation was not due to any disagreements regarding operations, policies, or practices.
🚩 Red Flags
- Immediate departure of a key scientific officer (CSO) can sometimes signal internal friction, though the filing explicitly denies this.
📋 Key Facts
- Adam Kaplin, M.D., Ph.D. resigned as Chief Scientific Officer on April 15, 2024.
- The resignation is effective immediately.
- The company stated the departure was not due to any disagreements with management or the Board of Directors.
MyMD Pharmaceuticals entered into an Omnibus Agreement with Series F Preferred Stock holders to defer missed installment payments and amend the Certificate of Designations. The amendment grants preferred holders voting rights on an as-converted basis and allows them to elect one director to the board.
🚩 Red Flags
- Liquidity/Cash Flow Stress: The company missed scheduled installment payments in March and April 2024, requiring a waiver from investors.
- Dilution & Control Risk: Preferred holders have gained significant voting power (as-converted basis) and the right to appoint a board member, indicating loss of control for common shareholders.
- Debt/Obligation Restructuring: The need to defer payments suggests immediate liquidity constraints.
📋 Key Facts
- The Company deferred installment payments due on March 1, 2024, and April 1, 2024, until May 1, 2024.
- Preferred holders waived breaches related to missing these installments.
- Amended Certificate of Designations allows Preferred Shares to vote with Common Stock on an as-converted basis (assuming a $60.21 conversion price).
- Preferred shareholders now have the right to elect one director by June 30, 2024.
- The Board of Directors was increased from six to seven members; Mitchell Glass appointed via preferred holder election.
The company filed an amendment to its previous 8-K to disclose a Certificate of Correction regarding its Certificate of Incorporation. This correction addresses an inadvertent error in the number of authorized shares of common stock.
🚩 Red Flags
- Inadvertent error in corporate charter regarding share authorization (though corrected via Certificate of Correction).
📋 Key Facts
- Filed on March 26, 2024, as Amendment No. 1 to the original report from March 7, 2024.
- The amendment corrects an inadvertent error in Paragraph A of Article IV of the Certificate of Incorporation.
- Corrected authorized shares of Common Stock: 16,666,666 shares.
- Corrected total number of shares authorized to be issued: 66,666,666 shares.
MyMD Pharmaceuticals, Inc. completed a reincorporation from New Jersey to Delaware via a merger with its wholly-owned subsidiary on March 4, 2024. This was a pre-approved administrative change intended to move the company's legal jurisdiction.
📋 Key Facts
- Effective Date of Reincorporation: March 4, 2024.
- The merger involved MyMD New Jersey merging into its wholly-owned subsidiary, MyMD Delaware.
- Stockholders approved the reincorporation at the 2023 Annual Meeting held on July 31, 2023.
- No change to company name (remains MyMD Pharmaceuticals, Inc.), management, fiscal year, or principal executive offices.
- Common stock retains the same CUSIP number and continues trading on Nasdaq under symbol 'MYMD'.
- The company is now governed by Delaware General Corporation Law.
MyMD Pharmaceuticals announced that it has regained compliance with the Nasdaq minimum bid price requirement. This filing serves to notify the market that the company is no longer in immediate danger of delisting due to share price non-compliance.
🚩 Red Flags
- Historical non-compliance with Nasdaq minimum bid price requirements indicates past volatility or liquidity issues.
📋 Key Facts
- The Company issued a press release on March 5, 2024, regarding compliance status.
- MyMD has regained compliance with The Nasdaq Stock Market's minimum bid price requirement.
- The disclosure is made under Item 7.01 (Regulation FD Disclosure).
MyMD Pharmaceuticals, Inc. has announced a 1-for-30 reverse stock split to increase its share price, effective February 14, 2024. This action significantly reduces the total number of outstanding shares and authorized shares.
🚩 Red Flags
- Reverse stock splits are often used to avoid delisting due to low share price (though the specific reason for this split is not explicitly stated in the text).
- Significant reduction in authorized shares may limit future equity financing capacity.
- The filing notes that Series F Preferred Stock and February 2023 Warrants have anti-dilution/price adjustment provisions triggered by a reverse split.
📋 Key Facts
- Reverse stock split ratio is 1-for-30.
- Effective date: February 14, 2024, at 4:05 p.m. ET.
- Outstanding shares will decrease from approximately 62,749,125 to approximately 2,091,638.
- Authorized shares will be reduced from 500 million to 16,666,666.
- New CUSIP number: 62856X201.
- Trading on a split-adjusted basis begins February 15, 2024, on Nasdaq.